Rockville-based stem cell biotechnology company, Neuralstem, who is poised to start its first ALS clinical trials, reported a wider net loss for its third quarter of $5.1 million, compared to a net loss of $3.2 million a year ago. The company has no revenue. In September, Neuralstem received US Food and Drug Administration approval to begin a Phase I trial for its ALS treatment, and expects to begin those trials in the first quarter of 2010. Neuralstem reports, however, that available funding is sufficient for the ALS clinical trials.
Click here to read more.Share this: